Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.

Asthma is a common allergic lung disease frequently affecting individuals with a prior history of eczema/atopic dermatitis (AD); however, the mechanism underlying the progression from AD to asthma (the so-called "atopic march") is unclear. Here we show that, like humans with AD, mice with...

Full description

Saved in:
Bibliographic Details
Main Authors: Shadmehr Demehri, Mitsuru Morimoto, Michael J Holtzman, Raphael Kopan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-05-01
Series:PLoS Biology
Online Access:https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000067&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849686731633197056
author Shadmehr Demehri
Mitsuru Morimoto
Michael J Holtzman
Raphael Kopan
author_facet Shadmehr Demehri
Mitsuru Morimoto
Michael J Holtzman
Raphael Kopan
author_sort Shadmehr Demehri
collection DOAJ
description Asthma is a common allergic lung disease frequently affecting individuals with a prior history of eczema/atopic dermatitis (AD); however, the mechanism underlying the progression from AD to asthma (the so-called "atopic march") is unclear. Here we show that, like humans with AD, mice with skin-barrier defects develop AD-like skin inflammation and are susceptible to allergic asthma. Furthermore, we show that thymic stromal lymphopoietin (TSLP), overexpressed by skin keratinocytes, is the systemic driver of this bronchial hyper-responsiveness. As an AD-like model, we used mice with keratinocyte-specific deletion of RBP-j that sustained high systemic levels of TSLP. Antigen-induced allergic challenge to the lung airways of RBP-j-deficient animals resulted in a severe asthmatic phenotype not seen in similarly treated wild-type littermates. Elimination of TSLP signaling in these animals blocked the atopic march, demonstrating that high serum TSLP levels were required to sensitize the lung to allergic inflammation. Furthermore, we analyzed outbred K14-TSLP(tg) mice that maintained high systemic levels of TSLP without developing any skin pathology. Importantly, epidermal-derived TSLP was sufficient to trigger the atopic march, sensitizing the lung airways to inhaled allergens in the absence of epicutaneous sensitization. Based on these findings, we propose that in addition to early treatment of the primary skin-barrier defects, selective inhibition of systemic TSLP may be the key to blocking the development of asthma in AD patients.
format Article
id doaj-art-71df762ecb14474ca89534d3d02d348d
institution DOAJ
issn 1544-9173
1545-7885
language English
publishDate 2009-05-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Biology
spelling doaj-art-71df762ecb14474ca89534d3d02d348d2025-08-20T03:22:35ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852009-05-0175e100006710.1371/journal.pbio.1000067Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.Shadmehr DemehriMitsuru MorimotoMichael J HoltzmanRaphael KopanAsthma is a common allergic lung disease frequently affecting individuals with a prior history of eczema/atopic dermatitis (AD); however, the mechanism underlying the progression from AD to asthma (the so-called "atopic march") is unclear. Here we show that, like humans with AD, mice with skin-barrier defects develop AD-like skin inflammation and are susceptible to allergic asthma. Furthermore, we show that thymic stromal lymphopoietin (TSLP), overexpressed by skin keratinocytes, is the systemic driver of this bronchial hyper-responsiveness. As an AD-like model, we used mice with keratinocyte-specific deletion of RBP-j that sustained high systemic levels of TSLP. Antigen-induced allergic challenge to the lung airways of RBP-j-deficient animals resulted in a severe asthmatic phenotype not seen in similarly treated wild-type littermates. Elimination of TSLP signaling in these animals blocked the atopic march, demonstrating that high serum TSLP levels were required to sensitize the lung to allergic inflammation. Furthermore, we analyzed outbred K14-TSLP(tg) mice that maintained high systemic levels of TSLP without developing any skin pathology. Importantly, epidermal-derived TSLP was sufficient to trigger the atopic march, sensitizing the lung airways to inhaled allergens in the absence of epicutaneous sensitization. Based on these findings, we propose that in addition to early treatment of the primary skin-barrier defects, selective inhibition of systemic TSLP may be the key to blocking the development of asthma in AD patients.https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000067&type=printable
spellingShingle Shadmehr Demehri
Mitsuru Morimoto
Michael J Holtzman
Raphael Kopan
Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
PLoS Biology
title Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
title_full Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
title_fullStr Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
title_full_unstemmed Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
title_short Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.
title_sort skin derived tslp triggers progression from epidermal barrier defects to asthma
url https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.1000067&type=printable
work_keys_str_mv AT shadmehrdemehri skinderivedtslptriggersprogressionfromepidermalbarrierdefectstoasthma
AT mitsurumorimoto skinderivedtslptriggersprogressionfromepidermalbarrierdefectstoasthma
AT michaeljholtzman skinderivedtslptriggersprogressionfromepidermalbarrierdefectstoasthma
AT raphaelkopan skinderivedtslptriggersprogressionfromepidermalbarrierdefectstoasthma